RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use

Abstract

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an influenza A viral genome. The influenza A viral (IAV) RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an influenza A viral genome at targeted portions of the genome that are conserved across a variety of known influenza A viral genome variants, and are therefore capable of inhibiting expression of various influenza A virus strains. Pharmaceutical compositions that include one or more IAV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described IAV RNAi agents to pulmonary cells, in vivo, provides for inhibition of influenza A viral genome expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases, disorders, and/or symptoms caused by influenza A viral infection.

CPC Classifications